Shared on 06 Nov 25
Fair value Increased 0.67%KURA: Upcoming FDA Decision Will Drive Momentum in Oncology Portfolio
Kura Oncology's fair value price target saw a modest increase from $27.00 to $27.18. Analysts cited updated financial metrics and maintained a cautious outlook following recent peer research coverage.
Shared on 01 May 25
Fair value Decreased 18%Upcoming FDA Approval Will Open New Oncology Avenues
Shared on 24 Apr 25
NDA Submission And Trial Progress Will Forge Market Opportunities
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 17 Apr 25
Fair value Increased 4.91%NDA Submission And Trial Progress Will Forge Market Opportunities
AnalystConsensusTarget has decreased profit margin from 19.3% to 17.3%.
Shared on 09 Apr 25
Fair value Decreased 3.63%NDA Submission And Trial Progress Will Forge Market Opportunities
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 02 Apr 25
Fair value Increased 26%NDA Submission And Trial Progress Will Forge Market Opportunities
AnalystConsensusTarget has increased profit margin from 10.5% to 19.3%, decreased future PE multiple from 91.0x to 67.6x and decreased shares outstanding growth rate from 0.1% to 0.1%.